showed that a killed suspension of Corynebacterium parvum was an unusually potent stimulant for the reticulo-endothelial (macrophage) system. A number of associated effects such as adjuvant activity (Neveu, Branellec and Biozzi, 1964; Biozzi et al., 1966) and increased resistance to bacterial (Adlam, Broughton and Scott, 1972) and protozoal (Nussenzweig, 1967) infection, have since been reported. The inhibitory effect of C. parvum pre-treatment on the growth of a range of experimental mouse tumours (Sarcoma J, Ehrlich ascites, a spontaneous mammary carcinoma, a methylcholanthrene-induced sarcoma and the AKR leukaemia) has been described (Halpern et al., 1966; Woodruff and Boak, 1966; Lamensans et al., 1968) . Although the results obtained here varied between the different systems, in general, conditions could be found under which C. parrum afforded a degree of protection. Currie and Bagshawe (1970) used a combination of C. parvum and chemotherapy against a methylcholanthreneinduced fibrosarcoma with some success, whereas Mathe, Pouillart and Lapeyraque (1969) were unable to influence an established L1210 tumour with a combination of C. parvum and immunotherapy.
The experiments described here are concerned with two aspects of the antitumour activities of C. parvum: the effect of simple pre-treatment and of pre-treatment followed by active immunization on the growth of a primary tumour challenge. Several mouse tumour systems, providing a variety of growth patterns and immunogenicities, have been used and the relationship between the effects of C. parvum and the characteristics of the tumours are discussed. The investigation formed a prelude to studies at the cell level and tissue culture lines have been established from the tumours described, in order to facilitate subsequent work in vitro.
MATERIALS AND METHODS
Mice. Tumourrs.The following tumours were obtained from the Chester Beatty Research Institute and maintained in ascitic form in the mice specified: R-I (radiation induced CBA leukaemia; Hewitt, 1962) in CBA-p; Hepatoma 129 (induced by CC13 in a C3H mouse, Andervont and Dunn, 1955) in CBA-p and BALB/c; Adj. PC6A (adjuvant induced BALB/c plasmacytoma, Potter and Robertson, 1960) in BALB/c and L5178 (DBA/2 leukaemia, Fischer, 1958) Hepatoma 129 grows rapidly from inocula of less than 10 cells and causes death with gross ascites and no evidence of metastases. Our form is not strain specific; originally a C3H tumour, it is routinely passaged in CBA against a minor histocompatibility barrier and a secondary strain is passaged in BALB/c mice against a strong histocompatibility barrier. There is little difference between the growth rate or minimum lethal dose of the two strains. The immunogenicity of irradiated cells is also similar, a dose of between 104 and 5 x 104 giving 50 % protection against a 100 cell challenge. The lack of strain specificity is not due to masking or loss of histocompatibility antigens, since BALB/c mice were readily immunized against the tumour by normal CBA spleen cells. L5178 leukaemia causes death essentially by massive i.p. growth with some local infiltration to form solid mesenterial growth. The F1 hybrid in which the tumour was passaged was within the major histocompatibility group (H-2d) of the strain of origin (DBA/2), thus minimizing any potential effects of allogeneic inhibition. The tumour was poorly immunogenic in this system and up to 107 irradiated cells were required for 500o protection against a 100 cell challenge.
PC6 plassmacytoma gives rise to massive ascites, with ready formation of a solid tumour at the injection site; it shows no evidence of metastasis. It is poorly immunogenic, with no protection against a 103 cell challenge with irradiated cell doses of up to 107.
Protective effects of pre-treatment with C. parnum Groups of 10 mice received 0-2 ml of C. parvum i.v. or i.p. 7 days before challenge with tumour cells. When C. parvum is administered 7 days before injection of sheep red cells it produces a marked adjuvant effect (Scott, unpublished results) .
RI leukaemia.-Challenge doses of both 10 and 100 cells were assayed (Fig  IA, B) . In all cases there was a definite protective effect from C. parvum which was highly significant at the lower challenge dose and with little difference between the i.v. and i.p. routes of administration. It was noticeable that prolongation of survival of animals incompletely protected by C. parvum was accompanied by greater ascites development. Very little protection from C. parvurn was (Fig. IC) . Hepatoma 129.-Challenges of both 10 and 100 cells in the CBA system and 100 cells in the BALB/c system were assayed ( Fig. 2A-C L5178 leukaemia.-The effect of C. parvum pre-treatment against a 100 cell challenge was minimal (Fig. 4) .
PC6 plasmacytoma. Pre-treatment again afforded only slighit protection against challenges of 1 03 and 1 04 cells (Fig. 4) . Combined pre-treatment with C. parvum and irradiated cells C. parvum was injected 7 days before immunization with irradiated cells and the animals were challenged after a further 7 days. Groups of 10 mice were used.
RI leukaemia. The results of combining immunization by 5 x 104 or 5 x 105 irradiated cells with i.v. C. parvum are shown in Fig. ID-F (Halpern et al., 1966; Woodruff and Boak, 1966; Lamensans et al., 1968 C. parvum, given before immunization, decreased the protective effect, although i.p. C. parvum in the H129 system did not influence the immune response. It seems that while C. parvum treatment stimulates the defences of the host against many tumours it may also, at least when given i.v., concomitantly depress some part of the immune response. Preliminary experiments both in vitro and in vivo have so far failed to reveal evidence for production of enhancing antibody and the fact that the depression can be overridden by larger immunizing doses also argues against such a mechanism. Enhanced growth of allogeneic tumour cells following immunization in conjunction with either complete or incomplete Freund's adjuvant has recently been reported (Zola, 1972) , and again no evidence of enhancing antibody could be found, the effect being attributed to depression of cell-mediated cytotoxicity. Evidence of depressed cell-mediated (T lymphocyte) responses following C. parvum treatment comes from the demonstration of reduced delayed hypersensitivity (Asherson and Allwood, 1971) , PHA responsiveness and GVH reactivity of lymphocytes (Scott, 1972) . Schedules for the immunotherapeutic treatment of human tumours have often included adjuvants, and C. parvum has begun to figure among these (Mathe, 1971) . The present finding that this agent, at least under certain experimental conditions, can show an immunosuppressive component in its action urges caution in this field.
